



March 8, 2013

Retrophin to Present at 25th Annual ROTH Conference

Clinical and corporate updates to be provided March 19 at 2:30 p.m. PT

New York, NY (March 8, 2013) – Retrophin, Inc. (OTCQB: RTRX), a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable patient options, today announced that Martin Shkreli, founder and chief executive officer, will be presenting at the 25th Annual ROTH Conference, which is being held March 17-20 in Dana Point, CA.

Details of the presentation are as follows:

Date: Tuesday, March 19
Time: 2:30 p.m. PT
Location: The Ritz-Carlton, Laguna Niguel

A webcast of the presentation will be available on Retrophin's web site: <http://www.retrophin.com/>.

About Retrophin

Retrophin is a biotechnology company focused on the discovery and development of orphan drugs for the treatment of rare and life-threatening diseases for which there are currently no viable patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin's lead compound, RE-021, is scheduled to begin enrollment in a potentially pivotal Phase 2 clinical trial for FSGS during the first half of 2013.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect the Company's business. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

#

Retrophin, Inc.
Martin Shkreli, CEO
(212) 983-1310
martin.shkreli@retrophin.com

Rx Communications Group
Paula Schwartz (Investors)
(917) 322-2216
pschwartz@rxir.com

6 Degrees
Annie Starr (Media)
(973) 415-8838
astarr@6degreespr.com